Shilpa Medicare’s marketing partner -- Amneal Pharmaceuticals has launched BORUZU, (Bortezomib for injection3.5mg/1.4ml), a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration in the U.S. market This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration The product has already been granted permanent J-code by U.S. Centers for Medicare & Medicaid Services (CMS).
BORUZU (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade, a lyophilized powder requiring reconstitution before use. Shilpa developed the molecule and Amneal will manufacture and commercialize the product.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1688.75 |
Dr. Reddys Lab | 1108.55 |
Cipla | 1433.45 |
Lupin | 1982.65 |
Zydus Lifesciences | 859.55 |
View more.. |